RT @EQRxINC: In top-line results from Phase 3 study in first-line treatment, our investigational therapy for EGFR-mutated #NSCLC met its pr…
RT @EQRxINC: In top-line results from Phase 3 study in first-line treatment, our investigational therapy for EGFR-mutated #NSCLC met its pr…
© Nextech Invest Ltd. | privacy policy